Ardelyx, Inc. (ARDX) Wednesday announced that China's Center for Drug Evaluation approved tenapanor to control serum phosphorus levels in dialysis patients with chronic kidney disease who do not respond to or cannot tolerate phosphorus binders.
This approval triggers a $5 million milestone payment from its partner, Shanghai Fosun Pharmaceutical.
Ardelyx is also eligible for up to $100 million in additional milestones and tiered royalties.
With over one million dialysis patients in China and a high prevalence of hyperphosphatemia, this approval addresses a significant unmet medical need.
Fosun Pharma will market tenapanor under the Chinese trade name Wan Ti Le.
ARDX is currently trading at $5.23, up 0.93 percent or $0.05 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.